MX2012008721A - (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4. - Google Patents

(r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.

Info

Publication number
MX2012008721A
MX2012008721A MX2012008721A MX2012008721A MX2012008721A MX 2012008721 A MX2012008721 A MX 2012008721A MX 2012008721 A MX2012008721 A MX 2012008721A MX 2012008721 A MX2012008721 A MX 2012008721A MX 2012008721 A MX2012008721 A MX 2012008721A
Authority
MX
Mexico
Prior art keywords
yloxy
methyl
isoxazol
pyran
piperidin
Prior art date
Application number
MX2012008721A
Other languages
English (en)
Inventor
Hirohide Noguchi
Nobuaki Waizumi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2012008721A publication Critical patent/MX2012008721A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Se describe en el presente documento (R)-4-((4-((4-(tetrahidrofura n-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tet rahidro-2H-piran-4-oI y su uso en el tratamiento de trastornos neurodegenerativos.
MX2012008721A 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4. MX2012008721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (en) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Publications (1)

Publication Number Publication Date
MX2012008721A true MX2012008721A (es) 2012-08-17

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008721A MX2012008721A (es) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.

Country Status (15)

Country Link
US (1) US20120041026A1 (es)
EP (1) EP2536713A1 (es)
JP (1) JP2013519722A (es)
KR (1) KR20120123089A (es)
CN (1) CN102762554A (es)
AR (1) AR080172A1 (es)
AU (1) AU2011216950A1 (es)
CA (1) CA2788656A1 (es)
IN (1) IN2012DN06631A (es)
MX (1) MX2012008721A (es)
SG (1) SG183111A1 (es)
TW (1) TW201141856A (es)
UY (1) UY33225A (es)
WO (1) WO2011101774A1 (es)
ZA (1) ZA201206469B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
BR112013029319A2 (pt) * 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4
RU2659036C2 (ru) * 2012-11-21 2018-06-27 Раквалиа Фарма Инк. Полиморфные формы
IN2013CH01199A (es) 2013-03-20 2015-08-14 Suven Life Sciences Ltd
CA2932428C (en) 2013-12-16 2017-10-24 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
JP6572414B2 (ja) * 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩
EP3265459B1 (en) 2015-02-13 2019-05-15 Suven Life Sciences Limited Amide compounds as 5-ht4 receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573562B1 (en) 1991-02-27 1996-04-24 Merrell Pharmaceuticals Inc. Dihydroquinoline NMDA antagonists
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
CA2149918A1 (en) * 1992-11-23 1994-06-09 Mark G. Palermo Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
BR9610733A (pt) 1995-09-29 1999-07-13 Glaxo Wellcome Spa Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
DE69707659T2 (de) 1996-04-12 2002-05-08 Aventis Pharma Inc Isatinderivate als acetylcholinesterase-inhibitoren und analgetika
WO1998000412A1 (en) 1996-07-01 1998-01-08 Schering Corporation Muscarinic antagonists
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
KR20000048715A (ko) 1996-09-30 2000-07-25 게리 디. 스트리트, 스티븐 엘. 네스비트 Ｎｍｄａ (ｎ-메틸-ｄ-아스파르테이트) 길항제
WO2000018391A1 (fr) 1998-09-30 2000-04-06 Takeda Chemical Industries, Ltd. Medicaments qui ameliorent le pouvoir de vidange de la vessie
DE60223904T2 (de) 2001-01-26 2008-11-27 Btg International Ltd. Benzylaminanalogen
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
MXPA04000737A (es) 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
RU2339630C2 (ru) 2003-06-04 2008-11-27 Мерк Энд Ко., Инк. 3-фторпиперидины в качестве антагонистов nmda/nr2b
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
LT2985039T (lt) * 2004-03-03 2018-11-12 Revance Therapeutics, Inc. Botulino toksinų vietinis taikymas ir jų įvedimas per odą
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
MX2007004458A (es) 2004-10-15 2007-08-08 Univ Rio De Janeiro Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes.
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
JP2009503520A (ja) 2005-07-29 2009-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベータアミロイド受容体及びその使用
CN101437510B (zh) 2006-03-20 2012-12-05 科学与工业研究会 用作乙酰胆碱酯酶抑制剂的药物组合物
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
ATE502026T1 (de) 2006-12-20 2011-04-15 Abbott Healthcare Products Bv Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
WO2008137474A1 (en) 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Morphinan compounds
CN101730706B (zh) 2007-05-11 2015-04-15 生物科技研究有限公司 具有神经保护和增强记忆活性的受体拮抗剂
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
WO2009036235A2 (en) 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
EP2296658A4 (en) 2008-05-09 2014-01-15 Univ Emory ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
UY33225A (es) 2011-09-30
CA2788656A1 (en) 2011-08-25
EP2536713A1 (en) 2012-12-26
TW201141856A (en) 2011-12-01
JP2013519722A (ja) 2013-05-30
IN2012DN06631A (es) 2015-10-23
KR20120123089A (ko) 2012-11-07
ZA201206469B (en) 2013-05-29
AR080172A1 (es) 2012-03-21
CN102762554A (zh) 2012-10-31
SG183111A1 (en) 2012-09-27
US20120041026A1 (en) 2012-02-16
WO2011101774A1 (en) 2011-08-25
AU2011216950A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
MX2012008721A (es) (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
HK1216887A1 (zh) 布魯頓酪氨酸激酶的抑制劑
HK1159099A1 (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd ccr2 copd -4-
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
MX339584B (es) Inhibidores de pi3 cinasa y usos de los mismos.
MX2019006655A (es) Antagonistas de actriib y dosificacion y uso de los mismos.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
MA32487B1 (fr) Nouvelles pyridine-2-ones et pyridazine-3-ones substituees
MX2010007784A (es) 2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran -4-il)-propionamida cristalina.
CR20120333A (es) Isoquinolinonas y quinazolinonas substituidas.
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
IL214501A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2324029A4 (en) HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT
SV2009003285A (es) Forma cristalina del hemihidrato de 1-(beta-d-glucopiranosil)-4-metil-3-[ 5-(4-fluorofenil)-2- tienilmetil] benceno
BRPI1011046A2 (pt) derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i
NZ724645A (en) Pde10 inhibitors and related compositions and methods
EP2161996A4 (en) CGRP RECEPTOR ANTAGONISTS BASED ON HETEROCYCLIC CARBOXAMIDE
EA201171063A1 (ru) Фармацевтические составы олмесартана
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
IL216802A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
ZA201008723B (en) Nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
NO20092634L (no) Fremgangsmate for fremstilling av piperazinyl og diazepanyl benzamidderivater
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal